Gilead to end coronavirus drug trials, adding to access worry: researchers

The drug was given emergency use authorization by the U.S. Food and Drug Administration on May 1, but hospitals are concerned about access. “We would like to see equitable and transparent distribution of this very precious resource,” Dr. Helen Boucher, chief of infectious diseases at Tufts Medical Center in Boston, told Reuters. Gilead’s studies – one in patients with severe COVID-19 and the other in moderate disease – have enrolled around 8,000 subjects, according to FDA statistics.